Whitehawk Therapeutics (WHWK) Accumulated Expenses (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Accumulated Expenses data on file, last reported at $759000.0 in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $759000.0, down 91.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $759000.0 (down 91.19% YoY), and the FY2025 annual result was $13.6 million, up 407.35% from the prior year.
• Accumulated Expenses declined to $759000.0 in Q1 2026 per WHWK's latest filing, from $13.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $14.9 million in Q4 2022 and troughed at $373000.0 in Q3 2025.
• A 5-year average of $9.2 million and a median of $10.6 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 1176.46% in 2022, then plunged 97.36% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $14.9 million in 2022, then dropped by 4.13% to $14.3 million in 2023, then tumbled by 81.26% to $2.7 million in 2024, then soared by 407.35% to $13.6 million in 2025, then slumped by 94.42% to $759000.0 in 2026.
• Business Quant data shows WHWK's Accumulated Expenses at $759000.0 in Q1 2026, $13.6 million in Q4 2025, and $373000.0 in Q3 2025.